Organoid Culture Cell Retention Patents: Who Leads, Where the Gaps Are 2026
- Bioreactor apparatus dominates the claim map. 78.3% of the 23 records in scope carry a C12M bioreactor/apparatus class, ahead of C12N cell-biology classes at 69.6% — retention is being claimed as a hardware problem more often than a biology one.
- Filing peaked in 2022 and has since cooled. Six of the 23 records publish in 2022 alone, the peak year so far; from 2021 (4) to 2024 (2) filing is down 50%, though 2025-2026 counts are still filling in given the ~18-month publication lag.
- The ranking has a leader but no dense middle. One assignee holds 6 records against a fifth-place count of 2 and a tenth-place count of 1 among the 10 ranked companies — a short head and a long, thin tail of single- or double-filing entrants.
Filing growth compares 2021 (4 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this dataset covers
This landscape tracks patent filings at the intersection of organoid and organotypic culture and the mechanics of keeping cells in place inside a culture device — retention efficiency, filter fouling, cell bleed, shear exposure, viable density and membrane pore behaviour. The scope is set by IPC classes C12N5/071, C12N5/00 and C12M3/00, which anchor the search in cell-culture biology and bioreactor apparatus rather than in organoid biology generally.
23 records fall inside this scope across 2015-2026, filed from receiving offices led by the United States (12), followed by the United Kingdom and WIPO's PCT route (3 each), Canada and Europe (2 each) and Singapore (1). The dataset is small enough that individual filings move the picture — read the shares and rankings below as directional, not as market law.
Filing trend and technology composition
Two views of the same 23 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
A short filing history with one clear peak
Filing in this scope starts from zero in 2017, climbs to a peak of 6 records in 2022, and then contracts: the 2021-to-2024 span shows a fall from 4 to 2 records, a 50% decline. Because publication trails filing by roughly 18 months, 2025 and 2026 are undercounted by construction and should not be read as a continued drop.
Apparatus classes outweigh biology classes
C12M (bioreactors and enzyme apparatus) appears on 78.3% of the 23 records and C12N (microorganisms and genetic engineering) on 69.6% — both counted against the same 23-record base, so the two shares overlap on many filings. G01N (material analysis and testing) sits at 43.5% and B01L (lab apparatus) at 30.4%, pointing to a field where measurement and hardware claims are as common as the underlying cell science. Medicinal (A61K, 13.0%), additive manufacturing (B33Y, 8.7%) and implant/therapeutic classes (A61F, A61P, 4.3% each) are present but marginal.
Shares are the percentage of the 23 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organoid Culture Cell Retention with Eureka
This page is one run against one query. Ask Eureka your own question about organoid culture cell retention and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this scope
Multilayered organ-on-a-chip systems and methods of use thereof
The disclosure provides for multilayered organ-on-a-chip systems that can be used to generate topographic neural organoids, and uses thereof, including as models to study neurological disorders.Filed by The Regents of the University of California, published 2022-08-18 as US20220259534A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2019222333A1 | Devices, systems and apparatuses for generating self-sustaining hypoxic conditions and gaseous and non-gaseou… | 31 |
| 2 | US20210087515A1 | Devices, systems and apparatuses for generating self-sustaining hypoxic conditions and gaseous and non-gaseou… | 16 |
| 3 | US20220106547A1 | Compositions and methods of using partial gel layers in a microfluidic device | 11 |
| 4 | US20190071627A1 | Micro-Fluidic Particle Concentrator and Filtering Device | 7 |
| 5 | US12270016B1 | Structure and function of modular microfluidic device for in-vitro modeling of human organs | 3 |
| 6 | CA3093581A1 | Devices, systems and apparatuses for generating self-sustaining hypoxic conditions and gaseous and non-gaseou… | 2 |
| 7 | WO2022175342A1 | Methods of expanding cholangiocytes | 1 |
| 8 | US20220259534A1 | Multilayered organ-on-a-chip systems and methods of use thereof | 1 |
| 9 | WO2022094613A1 | Cell isolation device and methods of use | 1 |
Citation counts accumulate with time in a searched corpus, so older records are structurally favoured — treat this table as a map of influence, not of current activity.
Publication numbers are shown where the record carries one (9 of 9 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for a filing decision
Three findings that shape where a new filing would land and what it would sit next to.
Retention is claimed as hardware first
More records carry a bioreactor/apparatus class (C12M) than a cell-biology class (C12N), even though both overlap heavily. Claims describing membrane geometry, flow paths and filter structure are at least as dense as claims on cell composition itself.
Activity crested in 2022
Filing rose to 6 records in 2022 before falling from 4 (2021) to 2 (2024), a 50% drop over that span. The 2025-2026 figures are not yet complete because of the roughly 18-month gap between filing and publication.
One assignee leads, the rest are thin
The leading assignee holds 6 of the ranked records; by fifth place the count is already down to 2, and the tenth-ranked entrant holds just 1. This is a ranking with a single clear leader rather than a dense competitive core.
Collaboration is limited and individual
Only 10 co-assignee pairs appear across the dataset, and the strongest links involve individual named inventors rather than corporate joint ventures — collaboration here looks more like shared inventorship than formal alliance filing.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organoid culture cell retention, with the prior art for and against each one.
The assignee landscape
Ten companies make up the entire ranking this dataset returns. It is not a top-50 or top-100 cut — it is the whole list, and it is short.
A single leader, no close second
The top assignee holds 6 of the 23 records in scope, well clear of the rest of the ranking. That lead is built on academic and institutional filings rather than a single dominant commercial player.
A thin middle tier
By fifth place, holdings have already dropped to 2 records, meaning most of the competitive differentiation happens in the top few positions rather than across a broad middle.
Single-filing entrants fill out the tail
The bottom of the ranking is made up of assignees with a single filing each, including individually named inventors rather than corporations — typical of a field still forming around a specific technical problem rather than consolidating around a few firms.
| Assignee | Recent year | YoY |
|---|---|---|
| University of North Carolina at Chapel Hill | 0 | — |
| Emulate, Inc. | 0 | — |
| Cambridge Enterprise Limited | 0 | — |
| École Polytechnique Fédérale de Lausanne (EPFL) | 0 | — |
| The Regents of the University of California | 0 | — |
| Alfaisal University | 0 | — |
| Frenaray Scientific, Inc. | 0 | — |
| WALTERS RYAN | 0 | — |
Where to take this analysis
The dataset points to a field with one clear institutional leader and open branches in apparatus design. These are the natural next steps for a team deciding where to file.
Map the apparatus claims in detail
Given how much of this scope sits in C12M and B01L classes, a claim-by-claim read of the bioreactor and lab-apparatus filings will show exactly which membrane and flow-path geometries are already occupied.
Explore apparatus claims in EurekaWatch the leader's next moves
With one assignee holding 6 of 23 records, tracking that portfolio's continuations and any new publications is the fastest way to anticipate where the field's densest prior art will grow next.
Track assignee activity in EurekaTest a filing in the under-claimed branches
The additive-manufacturing and implant-integration overlaps sit at single-digit record shares. A first claim drafted against that gap has more room to stand without immediately colliding with dense prior art.
Run a white-space search in EurekaCommon questions about this landscape
In this dataset, cell retention covers the mechanical and fluidic mechanisms that keep viable cells inside a culture device rather than losing them to the effluent stream — retention efficiency, filter fouling, cell bleed, shear exposure, viable density and membrane pore behaviour are the specific terms used to scope the search. Most of these claims sit in bioreactor and lab-apparatus classes (C12M, B01L) rather than pure cell-biology classes, meaning the inventive step is frequently in the hardware geometry rather than the cell line itself. A filing in this space typically pairs a device claim with a method-of-use claim describing how it maintains viable density over time.
The ranking returned by this dataset covers 10 companies, led by an assignee holding 6 of the 23 records in scope, with the count dropping to 2 by fifth place and 1 by tenth place. That pattern is a short head with a long, thin tail rather than a crowded competitive core, and the leading positions are held by academic and institutional assignees rather than a single large commercial filer. Because the ranked list is the entire dataset returned, not a top-50 or top-100 cut, absence from it does not necessarily mean a company is inactive — it may simply fall outside this specific IPC and keyword scope.
Filing peaked at 6 records in 2022, the highest single year in the dataset, and then declined from 4 records in 2021 to 2 in 2024 — a 50% drop over that span. That said, publication typically lags actual filing by around 18 months, so the apparent low counts in 2025 and 2026 are an artefact of that lag rather than confirmed evidence of a slowdown. The safest reading is that activity crested in 2022 and cooled through the most recently complete year, 2024, without drawing conclusions about the two most recent years.
US20220259534A1, assigned to The Regents of the University of California and published 2022-08-18, describes multilayered organ-on-a-chip systems used to generate topographic neural organoids, with stated use as models for studying neurological disorders. Its scope is a device architecture (multilayer chip) plus an application (neural organoid modelling for neurological disease study), rather than a specific retention mechanism such as a membrane pore design. Anyone building on multilayer organ-on-a-chip architectures for neural organoid work should review this filing's claims directly before assuming freedom to operate.
Based on IPC composition, the branches with the lowest record shares in this scope are additive-manufacturing overlap (B33Y, 8.7% of 23 records), implant integration (A61F, 4.3%) and therapeutic-activity-linked claims (A61P, 4.3%). These low counts suggest claim space that is not yet densely occupied, particularly around 3D-printed retention scaffolds and implant-integrated retention systems, though a small dataset means a handful of new filings could close these gaps quickly. A first claim in these branches should be checked against the leading assignee's broader portfolio, since institutional filers with device expertise are the most likely to extend into adjacent apparatus classes.
Research Organoid Culture Cell Retention in depth with Eureka
Go past this page: query the whole organoid culture cell retention corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.